Perrigo Company Faces Class Action Lawsuit Over Securities Fraud Allegations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Lawsuit Background: Levi & Korsinsky LLP has notified Perrigo Company investors of a class action lawsuit due to alleged securities fraud occurring between February 27, 2023, and November 4, 2025, aimed at recovering losses for affected investors.
- Allegations Details: The complaint alleges that Perrigo concealed significant underinvestment in maintenance and operational improvements in its infant formula business acquired from Nestlé, resulting in overstated financial results that misled investors about the company's earnings and cash flow.
- Investor Rights: Affected Perrigo investors have until January 16, 2026, to request to be appointed as lead plaintiff to participate in potential compensation, with no out-of-pocket costs required to join the lawsuit.
- Law Firm's Strength: With over 20 years of experience, Levi & Korsinsky has secured hundreds of millions for shareholders and has been recognized for seven consecutive years as one of the top securities litigation firms in the U.S., highlighting its expertise in complex securities litigation.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 27.50 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 14.860
Low
23.00
Averages
27.50
High
32.00
Current: 14.860
Low
23.00
Averages
27.50
High
32.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
